Repository logo
 
Publication

THOR is a targetable epigenetic biomarker with clinical implications in breast cancer

dc.contributor.authorApolónio, Joana
dc.contributor.authorDias, João S.
dc.contributor.authorFernandes, Mónica T.
dc.contributor.authorKomosa, Martin
dc.contributor.authorLipman, Tatiana
dc.contributor.authorZhang, Cindy H.
dc.contributor.authorLeão, Ricardo
dc.contributor.authorLee, Donghyun
dc.contributor.authorNunes, Nuno M.
dc.contributor.authorMaia, Ana-Teresa
dc.contributor.authorMorera, José L.
dc.contributor.authorVicioso, Luis
dc.contributor.authorTabori, Uri
dc.contributor.authorCastelo-Branco, Pedro
dc.date.accessioned2023-01-06T13:24:20Z
dc.date.available2023-01-06T13:24:20Z
dc.date.issued2022-12-18
dc.date.updated2023-01-01T04:54:15Z
dc.description.abstractBreast cancer (BC) is the most frequently diagnosed cancer and a leading cause of death among women worldwide. Early BC is potentially curable, but the mortality rates still observed among BC patients demon‑ strate the urgent need of novel and more efective diagnostic and therapeutic options. Limitless self-renewal is a hallmark of cancer, governed by telomere maintenance. In around 95% of BC cases, this process is achieved by telom‑ erase reactivation through upregulation of the human telomerase reverse transcriptase (hTERT). The hypermethylation of a specifc region within the hTERT promoter, termed TERT hypermethylated oncological region (THOR) has been associated with increased hTERT expression in cancer. However, its biological role and clinical potential in BC have never been studied to the best of our knowledge. Therefore, we aimed to investigate the role of THOR as a biomarker and explore the functional impact of THOR methylation status in hTERT upregulation in BC.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationClinical Epigenetics. 2022 Dec 18;14(1):178pt_PT
dc.identifier.doi10.1186/s13148-022-01396-3pt_PT
dc.identifier.eissn1868-7083
dc.identifier.urihttp://hdl.handle.net/10400.1/18744
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relationCentre for Biomedical Research
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.titleTHOR is a targetable epigenetic biomarker with clinical implications in breast cancerpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleCentre for Biomedical Research
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UID%2FBIM%2F04773%2F2013/PT
oaire.citation.issue1pt_PT
oaire.citation.startPage178pt_PT
oaire.citation.titleClinical Epigeneticspt_PT
oaire.citation.volume14pt_PT
oaire.fundingStream6817 - DCRRNI ID
person.familyNameApolónio
person.familyNameMaia
person.familyNameCastelo-Branco
person.givenNameJoana
person.givenNameAna-Teresa
person.givenNamePedro
person.identifier.ciencia-id791E-9E39-2795
person.identifier.ciencia-idE015-7F8F-5CA1
person.identifier.orcid0000-0002-9727-1813
person.identifier.orcid0000-0002-0454-9207
person.identifier.orcid0000-0002-3453-3978
person.identifier.ridF-4404-2012
person.identifier.scopus-author-id14319300100
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication01cf2be1-ea9f-4082-bcc6-e50fe4ad9fe1
relation.isAuthorOfPublication229d470e-6eb8-4144-a68a-5e0d5bec8a2c
relation.isAuthorOfPublicationbb25b5ad-1769-42be-a7d3-8fe76215aa23
relation.isAuthorOfPublication.latestForDiscoverybb25b5ad-1769-42be-a7d3-8fe76215aa23
relation.isProjectOfPublicationa385f051-757a-4626-8a4a-749b6a096835
relation.isProjectOfPublication.latestForDiscoverya385f051-757a-4626-8a4a-749b6a096835

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
13148_2022_Article_1396.pdf
Size:
2.2 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description: